These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 28274648)

  • 21. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
    Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
    Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Patients' experiences of continued treatment with extended-release naltrexone: a Norwegian qualitative study.
    Marciuch A; Brenna IH; Weimand B; Solli KK; Tanum L; Røstad BK; Birkeland B
    Addict Sci Clin Pract; 2022 Jul; 17(1):36. PubMed ID: 35850782
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence.
    Earley PH; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
    J Addict Med; 2017; 11(3):224-230. PubMed ID: 28358754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond?
    Nunes EV; Krupitsky E; Ling W; Zummo J; Memisoglu A; Silverman BL; Gastfriend DR
    J Addict Med; 2015; 9(3):238-43. PubMed ID: 25901451
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Employment-based reinforcement of adherence to an FDA approved extended release formulation of naltrexone in opioid-dependent adults: a randomized controlled trial.
    DeFulio A; Everly JJ; Leoutsakos JM; Umbricht A; Fingerhood M; Bigelow GE; Silverman K
    Drug Alcohol Depend; 2012 Jan; 120(1-3):48-54. PubMed ID: 21782353
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intramuscular extended-release naltrexone: current evidence.
    Gastfriend DR
    Ann N Y Acad Sci; 2011 Jan; 1216():144-66. PubMed ID: 21272018
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness, Implementation and Real-World Experience with Extended-Release Naltrexone (XR-NTX): A Special Issue of JSAT.
    Friedmann PD; Dunn KE; Nunes EV; O'Brien CP
    J Subst Abuse Treat; 2018 Feb; 85():31-33. PubMed ID: 29273249
    [No Abstract]   [Full Text] [Related]  

  • 28. Extended-release naltrexone for alcohol and opioid dependence: a meta-analysis of healthcare utilization studies.
    Hartung DM; McCarty D; Fu R; Wiest K; Chalk M; Gastfriend DR
    J Subst Abuse Treat; 2014 Aug; 47(2):113-21. PubMed ID: 24854219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Design of a randomized controlled trial of extended-release naltrexone versus daily buprenorphine-naloxone for opioid dependence in Norway (NTX-SBX).
    Kunøe N; Opheim A; Solli KK; Gaulen Z; Sharma-Haase K; Latif ZE; Tanum L
    BMC Pharmacol Toxicol; 2016 Apr; 17(1):18. PubMed ID: 27121539
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predictors of Continued Use of Extended-Released Naltrexone (XR-NTX) for Opioid-Dependence: An Analysis of Heroin and Non-Heroin Opioid Users in Los Angeles County.
    Cousins SJ; Radfar SR; Crèvecoeur-MacPhail D; Ang A; Darfler K; Rawson RA
    J Subst Abuse Treat; 2016 Apr; 63():66-71. PubMed ID: 26823295
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A demonstration project implementing extended-release naltrexone in Los Angeles County.
    Cousins SJ; Denering L; Crèvecoeur-MacPhail D; Viernes J; Sugita W; Barger J; Kim T; Weimann S; Rawson RA
    Subst Abus; 2016; 37(1):54-62. PubMed ID: 26158698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail.
    Gordon MS; Mitchell SG; Blue TR; Vocci FJ; Fishman MJ; Murphy SM; Couvillion K; Maher K; Ryan D; Wenzel K; Danner ML; Jarvis DK
    J Subst Abuse Treat; 2021 Sep; 128():108241. PubMed ID: 33339633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis.
    Hoffman KA; Baker R; Fanucchi LC; Lum PJ; Kunkel LE; Ponce Terashima J; McCarty D; Jacobs P; Korthuis PT
    Addict Sci Clin Pract; 2021 Nov; 16(1):67. PubMed ID: 34758887
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.
    Friedmann PD; Wilson D; Hoskinson R; Poshkus M; Clarke JG
    J Subst Abuse Treat; 2018 Feb; 85():45-48. PubMed ID: 28527855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.
    Krupitsky E; Nunes EV; Ling W; Gastfriend DR; Memisoglu A; Silverman BL
    Addiction; 2013 Sep; 108(9):1628-37. PubMed ID: 23701526
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Reduced cigarette smoking during injectable extended-release naltrexone treatment for opioid use disorder.
    Wang AL; Shi Z; Elman I; Langleben DD
    Am J Drug Alcohol Abuse; 2020 Jul; 46(4):472-477. PubMed ID: 32379516
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlates of retention on extended-release naltrexone among persons living with HIV infection transitioning to the community from the criminal justice system.
    Springer SA; Brown SE; Di Paola A; Altice FL
    Drug Alcohol Depend; 2015 Dec; 157():158-65. PubMed ID: 26560326
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term follow-up study of community-based patients receiving XR-NTX for opioid use disorders.
    Williams AR; Barbieri V; Mishlen K; Levin FR; Nunes EV; Mariani JJ; Bisaga A
    Am J Addict; 2017 Jun; 26(4):319-325. PubMed ID: 28328148
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial.
    Solli KK; Kunoe N; Latif ZE; Sharma-Haase K; Opheim A; Krajci P; Gaulen Z; Šaltytė Benth J; Tanum L
    Eur Addict Res; 2019; 25(6):303-309. PubMed ID: 31340204
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outpatient transition to extended-release injectable naltrexone for patients with opioid use disorder: A phase 3 randomized trial.
    Bisaga A; Mannelli P; Yu M; Nangia N; Graham CE; Tompkins DA; Kosten TR; Akerman SC; Silverman BL; Sullivan MA
    Drug Alcohol Depend; 2018 Jun; 187():171-178. PubMed ID: 29674251
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.